we also anticipate adjusted earnings per share of approximately $num-one in fiscal year-six.
for the full fiscal year year-six, we anticipate revenue of approximately $num-one million.
qtr-two revenue of $num-one million declined num-two basis points on an organic basis versus the prior year, which excludes the effects of foreign currency.
by segment, north america revenues were up num-one%, positively impacted by the women's health analgesics, oral care and ear and eye care categories, partially offset by lower cough and cold and gi shipments at certain categories we participate in face declines in incidence levels and usage rates related to covid.
advertising and marketing came in at num-one% of revenue in qtr-two and num-two% for the first six months.
for the first half, our revenues were down num-one basis points, excluding foreign currency.
in the second quarter, we generated $num-one million in free cash flow, which was lower than last year due to planned capex investments.
adjusted ebitda and earnings per share for the second quarter grew approximately num-one% and num-two%, respectively, versus the prior year.
total company gross margin of num-one% was flat to last year's adjusted gross margin and stable to recent quarters.
we expect a&m for the full year to be just under num-one% as a percent of sales as we continue at a normalized rate of spend in the second half.
for the full year, we anticipate g&a expenses to approximate num-one% and remain below prior year in absolute dollars.
our international business declined approximately num-one% after excluding foreign currency.
in the second quarter, we continued to focus on debt reduction and paid down $num-one million in debt.
first half fiscal year-six total free cash flow of $num-one million grew num-two% versus the prior year.
free cash flow is expected to be at or above last year's level of $num-one million.
for the full year fiscal year-six, we expect interest expense to approximate $num-one million.